Publications by authors named "Gerd-R Burmester"

Claim this Profile
C
Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
Rieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Andrew Östör

Rheumatol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease.
Gerd R Burmester, Atul Deodhar, Alan D Irvine, Remo Panaccione, Kevin L Winthrop

Adv Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study.
Andreas Hess, Koray Tascilar, Hanna M Schenker, Laura Konerth, Verena Schönau, Gerd R Burmester

Lancet Rheumatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To optimise the diagnostic process of rheumatic diseases affecting the hands using fluorescence optical imaging (FOI).
Nele Stumper, Jörn Berger, Jens Klotsche, Egbert Gedat, Paula Hoff, Gerd R Burmester

RMD Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease.
Gerd R Burmester, Eduardo Mysler, Peter Taylor, Stephen Hall, Bettina Wick-Urban

RMD Open· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, Daniel Aletaha, Johan Askling, Gerd R Burmester

Ann Rheum Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rheumatoid factors revisited in the age of biologic therapy.
Ali Berkant Avci, Eugen Feist, Gerd R Burmester

Rheumatology (Oxford)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration.
Kenneth Frank Baker, Julia Spierings, Martin Brom, Timothy Radstake, Emma Smith, Gerd R Burmester

Ann Rheum Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
Eden Sebbag, Kim Lauper, Juan Molina-Collada, Daniel Aletaha, Johan Askling, Gerd R Burmester

Ann Rheum Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.
Bayram Farisogullari, Saskia Lawson-Tovey, Kimme L Hyrich, Laure Gossec, Loreto Carmona, Gerd R Burmester

Ann Rheum Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Head-to-head studies in rheumatology].
Gerd R Burmester, Frank Behrens

Z Rheumatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
Josef S Smolen, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska, Gerd R Burmester

RMD Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.
Gerd R Burmester, Jacques-Eric Gottenberg, Roberto Caporali, Kevin L Winthrop, Yoshiya Tanaka

Ann Rheum Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).
Gerd R Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu

J Rheumatol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, MinKyu Park, JunGi Hwang, Gerd R Burmester

Expert Opin Biol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Gerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F Azevedo

Rheumatol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos, Gerd R Burmester

Ann Rheum Dis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis.
Jeffrey A Sparks, Philippe Dieudé, Anna-Maria Hoffmann-Vold, Gerd R Burmester, Simon Lf Walsh

BMC Rheumatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.
Juergen Rech, Koray Tascilar, Melanie Hagen, Arnd Kleyer, Bernhard Manger, Gerd R Burmester

Lancet· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials.
Eduardo Mysler, Gerd R Burmester, Christopher D Saffore, John Liu, Lani Wegrzyn

Adv Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years.
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, Ernest Choy, Daniel E Furst, Gerd R Burmester

Rheumatol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.
Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, Herbert Kellner, Uta Kiltz, Gerd R Burmester

RMD Open· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study.
Chiara Tani, Chiara Cardelli, Roberto Depascale, Anna Gamba, Luca Iaccarino, Gerd R Burmester

J Transl Autoimmun· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obexelimab in IgG4-related disease: B-cell inhibition as a novel therapeutic approach.
Tobias Alexander, Gerd R Burmester

Lancet Rheumatol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
Michaela Koehm, Tanja Rossmanith, Ann C Foldenauer, Eva Herrmann, Jan Brandt-Jürgens, Gerd R Burmester

Lancet Rheumatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis